These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12934161)

  • 1. Peginterferons in hepatitis C virus: virological, pharmacokinetic, and clinical implications. Introduction.
    Keeffe EB
    Semin Liver Dis; 2003; 23 Suppl 1():1-2. PubMed ID: 12934161
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.
    Fried MW; Hadziyannis SJ
    Semin Liver Dis; 2004; 24 Suppl 2():47-54. PubMed ID: 15346246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus therapy to date.
    Foster G; Mathurin P
    Antivir Ther; 2008; 13 Suppl 1():3-8. PubMed ID: 18432157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).
    Silva M; Poo J; Wagner F; Jackson M; Cutler D; Grace M; Bordens R; Cullen C; Harvey J; Laughlin M
    J Hepatol; 2006 Aug; 45(2):204-13. PubMed ID: 16780997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate.
    Diago M; Olveira A; Solá R; Romero-Gómez M; Moreno-Otero R; Pérez R; Salmerón J; Enríquez J; Planas R; Gavilán JC; Del Olmo J; Uribarrena R; Sillero C; Benítez A; Sánchez-Galdón S; Dalmau B; Eraña L; Montoro M; Portu J; Garijo JM; Barniol R; Domínguez A; Rota R; Olcoz JL; Antón M; Pamplona X; Casanovas T; Jiménez E; Huarte M; Díaz F; Sánchez-Ruano J; Orive M; Muñoz-Sánchez M; Roset M
    Aliment Pharmacol Ther; 2007 Apr; 25(8):899-906. PubMed ID: 17402993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients.
    Diago M; Crespo J; Olveira A; Pérez R; Bárcena R; Sánchez-Tapias JM; Muñoz-Sánchez M; Romero-Gómez M
    Aliment Pharmacol Ther; 2007 Oct; 26(8):1131-8. PubMed ID: 17894655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peginterferon and ribavirin for hepatitis C.
    Abramowicz M
    N Engl J Med; 2007 Mar; 356(12):1270-1; author reply 1271. PubMed ID: 17378100
    [No Abstract]   [Full Text] [Related]  

  • 8. Chronic hepatitis C virus infection in 2013--quo vadis?
    Prelipcean CC; Mihai C
    Rev Med Chir Soc Med Nat Iasi; 2013; 117(1):7-10. PubMed ID: 24505885
    [No Abstract]   [Full Text] [Related]  

  • 9. [Successful therapy with pegylated interferon alfa-2a. Hepatitis C patients remain virus-free].
    MMW Fortschr Med; 2003 Sep; 145(35-36):56. PubMed ID: 14584218
    [No Abstract]   [Full Text] [Related]  

  • 10. Peginterferon and ribavirin for hepatitis C.
    Duggan AE; Duggan JM
    N Engl J Med; 2007 Mar; 356(12):1269; author reply 1271. PubMed ID: 17377169
    [No Abstract]   [Full Text] [Related]  

  • 11. ADVANCE study begins enrollment.
    AIDS Patient Care STDS; 2008 Apr; 22(4):345. PubMed ID: 18422463
    [No Abstract]   [Full Text] [Related]  

  • 12. Response-guided therapy: optimizing treatment now and in the future.
    Marcellin P; Rizzetto M
    Antivir Ther; 2008; 13 Suppl 1():1-2. PubMed ID: 18432156
    [No Abstract]   [Full Text] [Related]  

  • 13. The treatment of viral hepatitis, present and future.
    Rodés J
    J Hepatobiliary Pancreat Surg; 2003; 10(2):163-7. PubMed ID: 14505150
    [No Abstract]   [Full Text] [Related]  

  • 14. Hepatitis C virus: five-year follow-up of patients with sustained virological response.
    Urquijo JJ; Diago M
    Rev Esp Enferm Dig; 2011 Feb; 103(2):53-5. PubMed ID: 21366364
    [No Abstract]   [Full Text] [Related]  

  • 15. Comment on the PROVE1 and PROVE2 clinical trials: "I was taking a picture of Rapid Virological Response with telaprevir, but the background is unfocused!".
    Baiocchi L; Lenci I; Carbone M; Angelico M
    Hepatology; 2009 Nov; 50(5):1676-7. PubMed ID: 19876945
    [No Abstract]   [Full Text] [Related]  

  • 16. Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.
    Taylor LE; Rich JD; Tashima KT
    N Engl J Med; 2004 Nov; 351(22):2340-2; author reply 2340-2. PubMed ID: 15564553
    [No Abstract]   [Full Text] [Related]  

  • 17. Characteristics of hepatitis C treatment with pegylated interferons and ribavirin.
    Jiménez-Méndez R; Castañeda-Hernández G
    Ann Hepatol; 2010; 9 Suppl():61-4. PubMed ID: 20713998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated IFNs for chronic hepatitis C: an update.
    Grace MJ; Cutler DL; Bordens RW
    Expert Opin Drug Deliv; 2005 Mar; 2(2):219-26. PubMed ID: 16296749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon and ribavirin for chronic hepatitis C.
    Hoofnagle JH; Seeff LB
    N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366
    [No Abstract]   [Full Text] [Related]  

  • 20. Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.
    Gholam PM
    N Engl J Med; 2004 Nov; 351(22):2340-2; author reply 2340-2. PubMed ID: 15570682
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.